A predictor score including night-time QT/RR dynamics identified a high-risk third of post-MI patients with a 1-year mortality of 36% vs 9% in the remaining patients (RR 4.0).
Cohort (n=241)
Does the QT/RR interval slope predict all-cause mortality in survivors of acute myocardial infarction with severe left ventricular dysfunction?
Night-time QT/RR dynamics, combined with age, ejection fraction, and QRS duration, independently predict all-cause mortality in high-risk survivors of myocardial infarction.
Effect estimate: RR 4.0
Absolute Event Rate: 36% vs 9%
OBJECTIVE: The purpose of this study was to evaluate the prognostic properties of the QT/RR relationship in survivors of myocardial infarction with severe left ventricular dysfunction. DESIGN: The QT/RR interval slope was assessed from 24-h electrocardiographic recordings obtained from 241 patients representative of survivors of an acute myocardial infarction with an ejection fraction < or =35%. During a median follow-up of 752 days, 63 patients died. RESULTS: In a multivariate analysis QT/RR at night-time was an independent predictor of all-cause mortality. A linear all-cause mortality predictor score was calculated from age, ejection fraction, QRS duration and QT/RR night, allowing identification of a high-risk one-third of the patients with a relative risk of death at 4.0. CONCLUSION: This study demonstrates independent prognostic information of night-time QT/RR dynamics in patients at high risk after myocardial infarction. A linear predictor score calculated from age, ejection fraction, QRS duration and QT/RR night identifies a high-risk one-third of the patients with a 1-year mortality of 36% vs 9% in the remaining patients.
Hintze et al. (Tue,) conducted a cohort in Myocardial infarction with severe left ventricular dysfunction (n=241). Night-time QT/RR interval slope vs. Remaining patients (lower risk score) was evaluated on All-cause mortality (RR 4.0). A predictor score including night-time QT/RR dynamics identified a high-risk third of post-MI patients with a 1-year mortality of 36% vs 9% in the remaining patients (RR 4.0).